Cynata Therapeutics Limited CYYNF
Set alert
At close · Oct 30
- YTD
- -95.20%
- 1 year
- -93.90%
- Open
- 0.11
- Prev close
- 0.0072
- Mkt cap
- 1.75M
- Vol
- 220
- Avg vol
- 381
- EPS
- -0.02
- P/E
- 0.00
More statistics
- Low
- 0.11
- High
- 0.11
News
4 months ago seekingalpha.com
Cynata Therapeutics Limited (CYYNF) Discusses Phase II Acute Graft Versus Host Disease and Phase III Osteoarthritis Trial Results Transcript
Cynata Therapeutics Limited (CYYNF) Discusses Phase II Acute Graft Versus Host Disease and Phase III Osteoarthritis Trial Results Transcript
9 months ago seekingalpha.com
Cynata Therapeutics Limited (CYYNF) Discusses Imminent Clinical Trial Readouts and Key Milestones in Osteoarthritis and Graft-versus-Host Disease Transcript
Cynata Therapeutics Limited (CYYNF) Discusses Imminent Clinical Trial Readouts and Key Milestones in Osteoarthritis and Graft-versus-Host Disease Transcript
9 months ago defenseworld.net
Sensei Biotherapeutics (NASDAQ:SNSE) vs. Cynata Therapeutics (OTCMKTS:CYYNF) Critical Analysis
Cynata Therapeutics (OTCMKTS:CYYNF - Get Free Report) and Sensei Biotherapeutics (NASDAQ: SNSE - Get Free Report) are both small-cap medical companies, but which is the better investment? We will…
10 months ago defenseworld.net
Cynata Therapeutics (OTCMKTS:CYYNF) vs. Exelixis (NASDAQ:EXEL) Financial Survey
Cynata Therapeutics (OTCMKTS:CYYNF - Get Free Report) and Exelixis (NASDAQ: EXEL - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies…
11 months ago seekingalpha.com
Cynata Therapeutics Limited (CYYNF) Discusses Clinical Trial Progress and Corporate Developments Including GVHD, Osteoarthritis, and Kidney Transplantation Transcript
Cynata Therapeutics Limited (OTCPK:CYYNF) Discusses Clinical Trial Progress and Corporate Developments Including GVHD, Osteoarthritis, and Kidney Transplantation November 5, 2025 8:30 PM EST Company…
1 year ago seekingalpha.com
Cynata Therapeutics Limited (CYYNF) Q4 2025 Earnings Call Transcript
Cynata Therapeutics Limited (OTCPK:CYYNF) Q4 2025 Earnings Conference Call August 4, 2025 9:00 PM ET Company Participants Kilian Kelly - MD, CEO & Director Mathias Kroll - Chief Business Officer…
1 year ago seekingalpha.com
Cynata Therapeutics Limited (CYYNF) Investor Webinar Transcript
Cynata Therapeutics Limited (OTCPK:CYYNF) Investor Webinar Conference Call February 5, 2025 6:30 PM ET Company Participants Lauren Nowak - Media Relations Kilian Kelly - Chief Executive Officer and…
5 years ago seekingalpha.com
Longeveron Seeks $25 Million IPO For Anti-Aging Efforts
Longeveron Seeks $25 Million IPO For Anti-Aging Efforts